Neridronate

Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of osteogenesis imperfecta (OI) and Paget’s disease of bone (PDB) . Neridronate is effective also in other skeletal diseases such as osteoporosis, algodystrophy, hypercalcemia of malignancy, and bone metastases[1][2].

Product Specifications

CAS Number

[79778-41-9]

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/neridronate.html

Purity

98.0

Solubility

H2O : 5 mg/mL (ultrasonic; warming; adjust pH to 8 with NaOH; heat to 60°C)

Smiles

OC(P(O)(O)=O)(CCCCCN)P(O)(O)=O

Molecular Formula

C6H17NO7P2

Molecular Weight

277.15

Precautions

H302, H315, H319, H335

References & Citations

[1]Gatti D, et al. Clinical development of neridronate: potential for new applications. Ther Clin Risk Manag. 2013;9:139-47.|[2]Guiducci L, et al. Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study. Int J Endocrinol. 2019 Feb 6;2019:9802827.